| http://www.w3.org/ns/prov#value | - These studies have generally reported some benefits in recurrence rates and/or DFS. One RCT in patients with hepatocellular carcinoma and 1 retrospective study in patients with NSCLC reported improved OS. This body of evidence is limited by the context of the studies (non-U.S.), small sample sizes, heterogeneous treatment groups, and other methodological weaknesses.
|
